




RealRate

PHARMACEUTICAL 2020

Diffusion Pharmaceuticals Inc.
Rank 183 of 362



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2020

Diffusion Pharmaceuticals Inc. Rank 183 of 362

The relative strengths and weaknesses of Diffusion Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Diffusion Pharmaceuticals Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 275% points. The greatest weakness of Diffusion Pharmaceuticals Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 330% points.

The company's Economic Capital Ratio, given in the ranking table, is -183%, being 119% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	14,650
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,721
Liabilities, Non-Current	200
Other Assets	9,208
Other Compr. Net Income	0
Other Expenses	333
Other Liabilities	2,055
Other Net Income	-11,466
Property and Equipment	252
Research and Development	0
Revenues	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	24,111
Liabilities	3,976
Expenses	333
Stockholders Equity	20,134
Net Income	-11,799
Comprehensive Net Income	-11,799
Economic Capital Ratio	-183%

